Understanding the Market | HENLIUS rises over 4% as two latest research results of SLR171 in the field of gastric cancer are selected for IGCC 2025
HENLIUS's stock price rose by more than 4%, with an increase of 4.45% as of the time of publication, priced at HKD 31.7, with a transaction volume of HKD 25.5134 million. The company's independently developed monoclonal antibody H drug's two gastric cancer research results were selected for the 2025 International Gastric Cancer Conference. The H drug has been approved in multiple countries for the treatment of various cancers
According to the Zhitong Finance APP, HENLIUS (02696) rose over 4%, with a current increase of 4.45%, priced at HKD 31.7, and a trading volume of HKD 25.5134 million.
In terms of news, according to market reports, the 16th International Gastric Cancer Congress (IGCC 2025), hosted by the International Gastric Cancer Association (IGCA), will be held from May 7 to 10, 2025, in Amsterdam, Netherlands. At this congress, the latest research results in the field of gastric cancer for the innovative monoclonal antibody H drug Hanshu (sulfurly monoclonal antibody, European trade name: Hetronifly) developed by HENLIUS have been selected. Among them, the Phase II study of sulfurly monoclonal antibody for neoadjuvant chemoradiotherapy in esophagogastric junction adenocarcinoma has been selected for an oral presentation at the congress.
It is reported that H drug Hanshu is the world's first approved anti-PD-1 monoclonal antibody for first-line treatment of small cell lung cancer, and has been approved for marketing in more than 30 countries and regions including China, Europe, and Southeast Asia. So far, the H drug has been approved for the treatment of squamous non-small cell lung cancer (sqNSCLC), extensive stage small cell lung cancer (ES-SCLC), esophageal squamous cell carcinoma (ESCC), and non-squamous non-small cell lung cancer (nsNSCLC). Focusing on globally prevalent cancers such as lung cancer and gastrointestinal tumors, HENLIUS is simultaneously conducting over 10 clinical studies of immune combination therapies centered on the H drug globally, with a total enrollment of over 4,900 people in countries and regions including China, the United States, Japan, Turkey, Poland, and Georgia
